Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Findings Could Influence the Development of Therapies to Treat Dengue Disease

Published: Monday, August 05, 2013
Last Updated: Monday, August 05, 2013
Bookmark and Share
New research into the fight against Dengue may influence the development of anti-viral therapies that are effective against all four types of the virus.

The findings, led by researchers at the University of Bristol and published in the Journal of Biological Chemistry today [2 August], show for the first time that there may be significant differences in specific properties of the viral proteins for the four dengue virus types.

Due to the effects of globalisation, including increased travel and urbanisation of human populations and the expanded geographical distribution of the mosquito vector that is responsible for the transmission of viral infections to millions of people, the number of individuals afflicted with dengue is rising.

Infection with any one of the four types of dengue virus (DENV types 1 - 4) may result in a spectrum of illnesses ranging from dengue fever, a mild flu like illness which causes high fever and joint pains, to the potentially fatal dengue haemorrhagic fever.  Despite intensive research, dengue disease is not wholly understood, and there are no vaccines or anti-viral treatments available that can safely or effectively control the disease.

Dr Andrew Davidson, Senior Virologist and lead researcher from the University of Bristol, and colleagues examined the nuclear localisation properties of the NS5 protein of all four DENV types and found that there are major differences in the cellular localisation of the viral NS5 protein for the four DENV types.

The four types of DENV are genetically distinct. Although they can all cause dengue disease, little is known about how the genetic differences between them may translate into differences in virus replication and pathogenesis.

Previous studies by the team focusing on DENV-2, have shown that the viral NS5 protein is essential for DENV genome replication and is able to modulate the host immune response. As such, the NS5 protein is a key target for the development of anti-viral agents. Importantly, the team also showed that the DENV-2 NS5 protein accumulates in the nucleus during infection which is believed to effect host cell function.

Dr Davidson, Senior Lecturer in Virology, School of Cellular and Molecular Medicine at the University of Bristol, said: “The study shows for the first time that there may be significant differences in specific properties of the viral proteins for the four DENV types. This is important as it impacts on our understanding of viral replication and pathogenesis and the design of anti-viral therapies that are effective against all DENV types.”

Present studies in the laboratory are focused on comprehensively comparing the effects of different DENV types on the host cell, using the state-of-the-art proteomics facilities at the University of Bristol.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Monday, May 23, 2016
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Thursday, May 05, 2016
Alzheimer’s to Benefit from Landmark MRC-AstraZeneca Compound Collaboration
A study to investigate Alzheimer’s disease led by scientists at the University of Bristol has been awarded funding by the Medical Research Council (MRC).
Tuesday, November 06, 2012
Researchers Awarded Almost £1 Million to Target High Blood Pressure
Study shows that reduced blood flow to the brain will trigger high blood pressure.
Tuesday, August 21, 2012
Scientific News
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!